(HCAT) Health Catalyst - Ratings and Ratios
Data, Analytics, Technology, Services, Software
HCAT EPS (Earnings per Share)
HCAT Revenue
Description: HCAT Health Catalyst
Health Catalyst Inc (HCAT) is a healthcare technology company that provides data and analytics solutions to healthcare organizations in the US. The company operates through two main segments: Technology and Professional Services, offering a comprehensive data analytics platform called ignite, as well as various applications and expertise solutions to improve clinical and financial outcomes.
Key Performance Indicators (KPIs) for HCAT include revenue growth, customer acquisition and retention rates, and the expansion of its ignite platform and related services. The companys ability to drive adoption of its technology and services among healthcare providers is crucial, as is its capacity to deliver measurable improvements in patient outcomes and operational efficiency. Other important metrics include its gross margin, operating expenses as a percentage of revenue, and cash flow generation.
From a financial perspective, HCATs market capitalization is approximately $282.58 million, and its forward Price-to-Earnings ratio is 19.34, indicating that the market expects the company to grow earnings significantly in the future. However, the companys current Return on Equity (ROE) is negative, at -19.99%, suggesting that it is still in an investment phase, with significant expenditures driving growth.
To evaluate HCATs potential, its essential to monitor its progress in expanding its customer base, increasing revenue, and improving profitability. Key areas to watch include the companys ability to penetrate the healthcare technology market, its success in delivering ROI to its customers, and its capacity to manage operating expenses while investing in growth initiatives.
HCAT Stock Overview
| Market Cap in USD | 228m |
| Sub-Industry | Health Care Technology |
| IPO / Inception | 2019-07-25 |
HCAT Stock Ratings
| Growth Rating | -91.1% |
| Fundamental | 38.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -67.2% |
| Analyst Rating | 4.23 of 5 |
HCAT Dividends
Currently no dividends paidHCAT Growth Ratios
| Growth Correlation 3m | -67.3% |
| Growth Correlation 12m | -94.6% |
| Growth Correlation 5y | -93.6% |
| CAGR 5y | -33.06% |
| CAGR/Max DD 3y | -0.40 |
| CAGR/Mean DD 3y | -0.73 |
| Sharpe Ratio 12m | -0.88 |
| Alpha | -75.09 |
| Beta | 0.630 |
| Volatility | 60.13% |
| Current Volume | 776.7k |
| Average Volume 20d | 874.7k |
| Stop Loss | 2.9 (-7.3%) |
| Signal | -0.83 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-100.1m TTM) > 0 and > 6% of Revenue (6% = 19.0m TTM) |
| FCFTA -0.00 (>2.0%) and ΔFCFTA 6.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 25.86% (prev 19.38%; Δ 6.48pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.01 (>3.0%) and CFO -6.04m > Net Income -100.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (69.6m) change vs 12m ago 17.41% (target <= -2.0% for YES) |
| Gross Margin 45.31% (prev 31.83%; Δ 13.48pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 48.34% (prev 43.30%; Δ 5.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -3.05 (EBITDA TTM -35.5m / Interest Expense TTM 26.5m) >= 6 (WARN >= 3) |
Altman Z'' -5.22
| (A) 0.13 = (Total Current Assets 180.6m - Total Current Liabilities 98.8m) / Total Assets 616.2m |
| (B) -2.03 = Retained Earnings (Balance) -1.25b / Total Assets 616.2m |
| warn (B) unusual magnitude: -2.03 — check mapping/units |
| (C) -0.12 = EBIT TTM -80.8m / Avg Total Assets 654.0m |
| (D) 1.29 = Book Value of Equity 347.5m / Total Liabilities 268.6m |
| Total Rating: -5.22 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 38.55
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -0.64% = -0.32 |
| 3. FCF Margin -0.58% = -0.22 |
| 4. Debt/Equity 0.45 = 2.40 |
| 5. Debt/Ebitda -4.42 = -2.50 |
| 6. ROIC - WACC -18.06% = -12.50 |
| 7. RoE -27.72% = -2.50 |
| 8. Rev. Trend 95.53% = 4.78 |
| 9. Rev. CAGR 6.23% = 0.78 |
| 10. EPS Trend 65.49% = 1.64 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of HCAT shares?
Over the past week, the price has changed by -7.40%, over one month by +4.33%, over three months by -21.36% and over the past year by -60.97%.
Is Health Catalyst a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HCAT is around 1.83 USD . This means that HCAT is currently overvalued and has a potential downside of -41.53%.
Is HCAT a buy, sell or hold?
- Strong Buy: 7
- Buy: 2
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HCAT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.6 | 45.7% |
| Analysts Target Price | 4.6 | 45.7% |
| ValueRay Target Price | 2 | -36.1% |
Last update: 2025-09-05 04:45
HCAT Fundamental Data Overview
CCE Cash And Equivalents = 97.3m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 11.534
P/S = 0.7213
P/B = 0.654
Beta = 1.464
Revenue TTM = 316.1m USD
EBIT TTM = -80.8m USD
EBITDA TTM = -35.5m USD
Long Term Debt = 151.4m USD (from longTermDebt, last quarter)
Short Term Debt = 5.50m USD (from shortTermDebt, last quarter)
Debt = 156.9m USD (Calculated: Short Term 5.50m + Long Term 151.4m)
Net Debt = -29.3m USD (from netDebt column, last quarter)
Enterprise Value = 287.6m USD (228.0m + Debt 156.9m - CCE 97.3m)
Interest Coverage Ratio = -3.05 (Ebit TTM -80.8m / Interest Expense TTM 26.5m)
FCF Yield = -0.64% (FCF TTM -1.84m / Enterprise Value 287.6m)
FCF Margin = -0.58% (FCF TTM -1.84m / Revenue TTM 316.1m)
Net Margin = -31.67% (Net Income TTM -100.1m / Revenue TTM 316.1m)
Gross Margin = 45.31% ((Revenue TTM 316.1m - Cost of Revenue TTM 172.9m) / Revenue TTM)
Tobins Q-Ratio = 0.83 (Enterprise Value 287.6m / Book Value Of Equity 347.5m)
Interest Expense / Debt = 3.69% (Interest Expense 5.79m / Debt 156.9m)
Taxrate = 21.0% (US default)
NOPAT = -80.8m (EBIT -80.8m, no tax applied on loss)
Current Ratio = 1.83 (Total Current Assets 180.6m / Total Current Liabilities 98.8m)
Debt / Equity = 0.45 (Debt 156.9m / last Quarter total Stockholder Equity 347.5m)
Debt / EBITDA = -4.42 (Net Debt -29.3m / EBITDA -35.5m)
Debt / FCF = -85.32 (Debt 156.9m / FCF TTM -1.84m)
Total Stockholder Equity = 361.2m (last 4 quarters mean)
RoA = -16.25% (Net Income -100.1m, Total Assets 616.2m )
RoE = -27.72% (Net Income TTM -100.1m / Total Stockholder Equity 361.2m)
RoCE = -15.76% (Ebit -80.8m / (Equity 361.2m + L.T.Debt 151.4m))
RoIC = -11.93% (NOPAT -80.8m / Invested Capital 677.0m)
WACC = 6.13% (E(228.0m)/V(384.9m) * Re(8.34%)) + (D(156.9m)/V(384.9m) * Rd(3.69%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 2.29%
Discount Rate = 8.34% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -1.84m)
Revenue Correlation: 95.53 | Revenue CAGR: 6.23%
Rev Growth-of-Growth: -0.33
EPS Correlation: 65.49 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -61.77
Additional Sources for HCAT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle